Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325267 | 0.85 | ALDH1A1 (0.44) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2327991 | 0.83 | CETP (0.42) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2326268 | 0.83 | CETP (0.42) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL4270221 | 0.83 | CETP (0.42) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2343179 | 0.82 | CETP (0.40) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2326215 | 0.82 | SIGMAR1 (0.42) | CETPIDO1SIGMAR1 | |
| SCHEMBL2342265 | 0.80 | CETP (0.41) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2360056 | 0.80 | CETP (0.41) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2328175 | 0.80 | CETP (0.41) | CETPTSHRALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2323276 | 0.80 | CETP (0.41) | CETPTSHRALDH1A1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987881-B1 | METHOD FOR SEPARATION AND COLLECTION OF DIALKYL TIN DIALKOXIDE | ASAHI KASEI CHEMICALS CORP (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-7842828-B2 | Method for separating out and recovering dialkyltin dialkoxide | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20100160662-A1 | Method for Separating Out and Recovering Dialkyltin Dialkoxide | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1987881-A1 | METHOD FOR SEPARATION AND COLLECTION OF DIALKYL TIN DIALKOXIDE | Asahi Kasei Chemicals Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160662-A1 | Method for Separating Out and Recovering Dialkyltin Dialkoxide | ALOX5, ALOX15B, ALOX15 | CETP 139/4885TSHR 3272/4885ALDH1A1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.